Markets
Upside down house
So this is a story all about how our markets got flipped upside down (Juancho Torres/Getty Images)
Up Is Down

“Belated overreaction,” and why the American stock market has entered Bizarro World

The downs are up, the ups are down, cats and dogs living together, mass hysteria.

Luke Kawa

Congratulations if you’ve been having a great year picking stock and industry winners. But, if you have, you might also be having a crappy day.

The soft June CPI inflation print appears to be catalyzing a massive rotation within equity markets rather than outright strength at the index level, as the S&P 500 is down about 0.8%.

To overgeneralize, everything that has been working isn’t. And all the things that haven’t, are. 

Coming into today, the iShares Russell 2000 ETF (which tracks small cap stocks) was roughly flat year-to-date, while the MSCI USA Momentum Factor ETF (which bets that winners will keep winning) was up nearly 30%.

Today, the small-cap fund is surging while its momentum counterpart is falling. Its the biggest one-day underperformance of MTUM since January 6, 2021, a day memorable for that intra-market divergence and nothing else. Well, that was the session following the Georgia run-off elections that gave the Democrats the trifecta of House, Senate, and White House control, paving the way for more government spending. Still can’t remember anything else, though.

The gap between small caps and the tech titans is even larger: it’s their best day of relative performance since Pfizer announced progress on a vaccine that would help allow us to return to pre-pandemic patterns of spending and activity.

A Goldman Sachs basket of stocks that have been big losers over the past year is on fire, up 2.5% as of midday. A separate index from Goldman that tracks heavily shorted stocks is doing even better, up 2.9%.

It’s worth emphasizing that these huge below the surface moves going on are (by and large) more about massive gains in things that have lagged rather than big declines in things that have done well (with the noteworthy exception of the so-called Magnificent Seven group).

If portfolio managers are worried that their bets against certain companies might not continue to work, they typically don’t just buy back those companies to reduce their short exposure. They also tend to reduce their long bets (to maintain a constant degree of overall equity exposure).

There are some fundamental underpinnings behind the major rotation we’re seeing: higher confidence in rate cuts in a cooling (but not collapsing) economy should help protect the earnings power of the many, not just the few. And in the case of small caps, this cohort tends to have more floating rate debt than their large-cap peers, so lower short-term rates are more of a benefit to their bottom lines, too.

But all in all, the likelihood of a rate cut in September went from “high” before the inflation data this morning were released to “very high.” So why such a seismic under-the-hood shift?

Mark Dow, founder of Dow Global Advisors and Behavioral Macro, calls occurrences like these “belated overreaction” – in basic terms, when a specific piece of information or the way it’s presented just hits different, and everyone clues in at the same time.

“It was in the late 2000s on the desk at Pharo and a headline came across Bloomberg that was saying something important and negative for the market on an issue that had been a market focus – but there was no reaction,” he said.  “All us risk takers spent the next hour talking about it and doing nothing. A couple of hours later, though, the exact same headline came across Bloomberg again, but this time in all caps with the red backdrop. The market then reacted hard.”

The initial conditions of the market can play a big role in determining why and when investors tend to “wake up” to new information. And for weeks upon weeks, we’d been flagging poor breadth; the narrowness of the market and the underperformance of the average stock relative to the tech titans.

“News often hits different when markets have been running on a theme and psychology and positioning is leaning hard one way or another,” said Dow. “And then, boom, news all of a sudden matters.”

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.